Study of REN-1654 in Patients With Sciatica Pain

NCT ID: NCT00107055

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-12-31
• Study Completion Date: 2005-04-30

Brief Summary

The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with pain that radiates down the leg(s), and is typical of sciatica (lumbosacral radiculopathy). These patients will usually have a herniated disc that is causing compression on the nerves coming out of the spinal column.

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled study to determine the efficacy and tolerability of REN-1654 in subjects with sciatica. After screening and baseline clinical assessments, subjects will be randomly assigned to receive REN 1654 100 mg or matching placebo, once daily for 3 weeks. Leg pain, back pain and other efficacy measures will be assessed at 1 and 3 weeks after initiation of treatment. A subset of patients will undergo analysis of blood levels of REN-1654 during the course of the study (pharmacokinetics). Subjects will discontinue treatment after 3 weeks and return after a further 3 weeks off therapy for a final clinical assessment 6 weeks after initiation of treatment. If a subject does not return for follow-up, an effort will be made by telephone to document their clinical status and whether other interventions have been made.

Conditions

Sciatica; Herniated Disc; Radiculopathy

Keywords

Herniated nucleus pulposus; Lumbosacral radiculopathy; Anti-TNF alpha; Tumor necrosis factor alpha

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: ECT
• Blinding Strategy: DOUBLE

Interventions

REN-1654

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males or females, ages 18 to 55, able and willing to provide written informed consent to participate in the study.
• Able to read, understand and follow the study instructions, including completion of pain intensity rating scales.
• Leg pain radiating to or below the knee in a dermatomal pattern, diagnosed as being due to sciatica or lumbar or lumbosacral radiculopathy, the onset of which occurred 2 to 12 weeks prior to initiation of study treatment.
• Leg pain severity on a screening Categorical Pain Intensity Rating (for the prior 24 hour period) of at least 4, using an 11-point categorical pain intensity scale with 0 = no pain and 10 = worst pain imaginable.
• Leg pain on a screening Categorical Pain Intensity Rating rated as more severe than back pain.
• Positive straight leg raising (SLR) test as defined in Appendix B of this protocol.
• Subjects who are compliant in maintaining a Pain Diary between screening and baseline visits, and who record a 24-hour average Categorical Pain Intensity Rating score of at least 4 or greater on at least 3 days during the week prior to baseline visit.
• Subject who can maintain stable pharmacologic treatments for sciatica symptoms taken prior to dosing including analgesics, anti-inflammatory medications (e.g. NSAIDS), antidepressants, anticonvulsants, anxiolytics, or muscle relaxants. Subjects must be on stable doses of such medications for 2 weeks prior to the baseline visit, and maintained on the same doses throughout the study. Medications taken on an as-needed basis are permitted, and subjects will be asked to record daily usage of such medications in the subject diary.
• Subjects who at screening are receiving adjunctive analgesic therapy such as acupuncture or biofeedback should either discontinue it or establish a schedule of treatments that will remain consistent for 2 weeks prior to the baseline visit, and throughout the study.
• Subject with screening laboratory values within normal limits, or if abnormal must be considered not clinically significant and in the opinion of the Investigator not to place the subjects at risk.
• If female, must be post-menopausal, surgically sterile, not currently pregnant (verified by a screening pregnancy test) or nursing, and using a reliable contraception method such as intrauterine device (IUD), hormonal birth control pills, or double barrier method (male condom, female condom or diaphragm with spermicidal jelly).
• If male, must agree to use double-barrier methods of contraception.

Exclusion Criteria

• History of peripheral neuropathy or any other pain conditions with pain intensity equal to or greater than the pain associated with sciatica.
• Motor loss in a muscle corresponding to the affected dermatome graded as more than "trace".
• History of cauda equina syndrome, symptomatic scoliosis, spondylolisthesis (degenerative or isthmic), ankylosing spondylitis, rheumatoid arthritis or other inflammatory arthropathies. Degenerative arthritis is allowed.
• History of hepatic, cardiovascular, renal, gastrointestinal, hematological, neurological, endocrine (including diabetes), metabolic, pulmonary, immunological (including HIV infection) or psychiatric disease that in the opinion of the Investigator would pose a significant safety risk for a subject exposed to an investigational compound such as REN-1654.
• History of the following ophthalmic disorders based upon general medical review at the screening visit. Subjects will further undergo a screening ophthalmologic assessment. Should any of the following be identified at the screening ophthalmologic examination, the subject will be excluded from the study.

• Symptomatic cataract, resulting in any visual impairment (if a subject has been diagnosed with cataract to a degree that the cataract interferes with daily living and/or regarding which an ophthalmologist has recommended cataract surgery);
• Other vision-impairing disorders (if a subject is aware of any eye disorder that has impaired vision, such as age-related macular degeneration, lazy eye (amblyopia), double vision, or any optic nerve inflammation; presbyopia and other non-pathological visual acuity deficits are not exclusionary);
• Glaucoma or history of ocular hypertension (intraocular pressures greater than 21 mmHg).
• Cognitive or psychiatric disorders that may diminish compliance with study procedures, including maintenance of a daily pain diary and accurate dosing of study medication.
• Subjects who, at time of enrollment, have requested for or been advised by their physicians to receive local, regional, or spinal (articular, epidural, intrathecal or nerve root block) injections of medications for pain treatment or surgical intervention for their sciatica symptoms.
• Although subjects who report work-related injuries will be allowed to enroll, subjects will be excluded if they are involved in litigation related to the current episode of sciatica.
• Subjects with a screening creatinine laboratory value of ≥ 2.0 mg/dL.
• Screening liver enzyme results greater than the upper limit of the normal range
• Use of chemotherapy agents or history of cancer, other than basal cell carcinoma and squamous cell carcinoma, within five years prior to the screening visit.
• History of drug or alcohol abuse within one year prior to screening.
• Use within 2 weeks before start of study investigational compound dosing at baseline and through the end of the study of any investigational compound, any epidural, intrathecal, or nerve root block agent, corticosteroids, etanercept or other anti-TNF-α agent, topical anesthetics, or topical analgesics .
• Previous participation in another REN-1654 study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Renovis

INDUSTRY

Sponsor Role: lead

Principal Investigators

Randall W Moreadith, MD, PhD

Role: STUDY_DIRECTOR

Chief Medical Officer, Renovis, Inc.

Locations

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Advanced Clinical Therapeutics, LLC

Tuscon, Arizona, United States

Orthopaedic Spine Center at Stanford University Medical Center

Stanford, California, United States

Mile High Research Center

Denver, Colorado, United States

Clinical Research of West Florida

Clearwater, Florida, United States

Renstar Medical Research, Inc.

Ocala, Florida, United States

Suncoast Neuroscience Associates

St. Petersburg, Florida, United States

Emory Orthopaedics and Spine Center

Atlanta, Georgia, United States

Brigham & Women's Hospital, Pain Trials Center

Boston, Massachusetts, United States

Washington University School of Medicine, Pain Management Center

St Louis, Missouri, United States

A&A Pain Institute of St. Louis

St Louis, Missouri, United States

Research Across America

New York, New York, United States

Asheville Neurology Specialists, PA

Asheville, North Carolina, United States

Wake Research Associates

Raleigh, North Carolina, United States

The Cleveland Clinic Spine Institute

Cleveland, Ohio, United States

Lehigh Valley Hospital Neurosciences and Pain Research

Allentown, Pennsylvania, United States

Omega Medical Research

Warwick, Rhode Island, United States

Central Texas Spine Institute

Austin, Texas, United States

Advanced Clinical Research

West Jordan, Utah, United States

Countries

United States

References

Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001 Jun;6(2):67-72. doi: 10.1046/j.1529-8027.2001.01010.x.

Reference Type: BACKGROUND

PMID: 11446385 (View on PubMed)

Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren KA, Rantanen P, Tervonen O, Niinimaki J, Seitsalo S, Hurri H. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine (Phila Pa 1976). 2003 Apr 15;28(8):750-3; discussion 753-4.

Reference Type: BACKGROUND

PMID: 12698115 (View on PubMed)

Other Identifiers

REN-1654-2-03

Identifier Type: -

Identifier Source: org_study_id